NEW YORK, NY / ACCESSWIRE / December 3, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or "the Company") (NASDAQ:EGRX). Investors who purchased Eagle Pharmaceuticals securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/egrx.
The investigation concerns whether Eagle Pharmaceuticals has violated federal securities laws.
Investigation Details:
On November 9, 2023, Eagle Pharmaceuticals announced that "it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today . . . . The Company requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY(R) prior to filing its Form 10-Q. In addition, the Company expects to revise its previously disclosed 2023 full year guidance downward." Following this news, Eagle Pharmaceuticals' stock dropped $4.16 per share, or 30.36%, to close at $9.54 on November 9, 2023.
Then, on November 29, 2023, Eagle Pharmaceuticals announced that "[e]ffective immediately Scott Tarriff, Founder, President and Chief Executive Officer of the Company, has announced his resignation and retirement from his positions with the Company as President, Chief Executive Officer and Director on the Company's Board of Directors." Following this news, Eagle Pharmaceuticals' stock dropped $2.55 per share, or 30.98%, to close at $5.68 on November 29, 2023.
What's Next?
If you are aware of any facts relating to this investigation or purchased Eagle Pharmaceuticals securities, you can assist this investigation by visiting the firm's site: www.bgandg.com/egrx. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com:
https://www.accesswire.com/812298/eagle-pharmaceuticals-inc-egrx-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-seek-compensation-for-alleged-wrongdoings
